The U.S. Meals and Drug Administration (FDA) has accepted PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to assist establish sufferers with epithelial...
Minimal residual illness, or MRD, testing might have the potential to supply peace of thoughts to survivors of breast most cancers, as a survivor and...
When being handled for prostate most cancers, sufferers can place themselves to obtain the perfect care potential by seeing a multidisciplinary crew...
Though biomarker testing in early-stage non-small cell lung most cancers has improved, some sufferers nonetheless don't obtain full, guideline-recommended testing, in keeping...
For sufferers with high-risk HER2-positive early breast most cancers who've undergone neoadjuvant remedy, therapy with Enhertu (fam-trastuzumab deruxtecan-nxki) considerably improved invasive disease-free...
